As previously reported, on September 26, 2023, Alzamend was notified by Nasdaq that it did not meet the minimum market value of listed securities requirement for continued listing on Nasdaq under ...
Alzamend Neuro CEO Stephan Jackman to Participate in Maxim Group’s Virtual Healthcare Conference; Fireside Conversation on October 17th at 1:30 PM ET ...
The product candidates are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy product ...
Passive aggressive leadership in action. As a communications coach to executives and entrepreneurs all over the world, I’ve seen the team-building challenges that passive-aggressive ...
Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that it, Dr. Michael Newman ...